Financial Architects (New Jersey)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Financial Architects (New Jersey)’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-113	Closed	-$9K	–	1566
2016 Q4	$9K	Hold	113	–	–	﹤0.01%	1030
2016 Q3	$10K	Buy	+113	New	+$10.6K	﹤0.01%	997
2016 Q2	–	Sell	-18	Closed	-$1K	–	1431
2016 Q1	$1K	Buy	+18	New	+$1.47K	﹤0.01%	1121

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Financial Architects (New Jersey)'s BMRN Position: Q1 2017 in Review

Financial Architects (New Jersey) sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2017, closing a stake of 113 shares — an estimated $9K sold.

Financial Architects (New Jersey) first reported a position in BMRN in Q1 2016 and held it in 3 quarters. The position peaked at $10K in Q3 2016. 418 funds tracked by Wall St. Rank hold BMRN as of Q1 2017.

Financial Architects (New Jersey) reported no remaining BioMarin Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Financial Architects (New Jersey) sold 113 BioMarin Pharmaceuticals shares in Q1 2017, an estimated $9K.
Financial Architects (New Jersey) first reported a position in BioMarin Pharmaceuticals in Q1 2016 and held it in 3 quarters.
Financial Architects (New Jersey)'s BioMarin Pharmaceuticals position peaked at $10K in Q3 2016.
418 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2017.

Based on Financial Architects (New Jersey)'s 13F filing for Q1 2017, filed 26 Apr 2017.